snow
Events - Slide 1 Events - Slide 2 Events - Slide 3 Events - Slide 4

Welcome to Retina Specialists Northwest

Dedicated to delivering compassionate excellence in retinal and inflammatory eye disease always.

Retina Specialists Northwest, PLLC is an ophthalmic subspecialty practice focused on Retina and Uveitis. The practice philosophy is summarized in the company motto: Compassionate Excellence Always.

Board certified eye physician and surgeon, Dr. Brenda Myers-Powell

Dr. Myers-Powell and her staff are committed to delivering the best in personalized retinal care efficiently and effectively. Our pledge is to understand you as a whole and to provide the best available medical and surgical treatment tailored to your needs. We are centrally located between Seattle and Tacoma, at West Campus in Federal Way, strategically positioned to deliver quality care to residents within and outside the metropolitan areas. Our office is easily accessible from I-5, Hwy-18, Hwy-167, and Hwy-99. For your convenience, we are open most Saturdays.

We utilize the latest technology as well as clinical expertise to diagnose and manage all retinal and inflammatory disorders with particular attention to Retinal Tear and Detachment, Disorders of the Vitreous, Macular Holes, Diabetic Retinopathy, Age-related Macular Degeneration, Retinal Vascular Disease, Macular Edema, Scleritis, and vision-threatening Uveitis.

News from NEI

Brain Training May Bolster Visual Attention

People are bad at staying focused. We’ve all had our minds wander when we try to concentrate on a task that requires paying close attention but isn’t all that engaging. But a new NIH-funded study suggests that one’s capacity to stay focused can improve with real-time feedback.

“The reason we are bad at staying focused is because we are bad at monitoring our attentional state,” explained Nicholas Turk-Browne, Ph.D., associate professor in the Department of Psychology at Princeton University. Dr. Turk-Browne’s lab led the study published in Nature Neuroscience.

02/18/15 6:16 am

Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss

In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the National Institutes of Health.

English

02/16/15 8:31 am

HIV drugs show promise for “dry” AMD

A class of medications long used to curb HIV infection shows promise as a therapy for age-related macular degeneration (AMD), suggest findings from an NIH-funded study. These mainstay HIV drugs, called nucleoside reverse transcriptase inhibitors (NRTIs), may eventually be repurposed to treat a host of other inflammatory disorders, too.

12/22/14 7:44 am

NEI sets stage for new clinical trial to tackle dry eye

For some people it feels like a speck of sand in the eye, or stinging or burning that doesn’t go away. For others, dry eye disease (or simply dry eye) can become a chronic condition that leads to blurred vision or even vision loss if it goes untreated.

09/29/14 10:41 am

Health Education Leads to More Eye Exams in Group at Risk for Vision Loss

Researchers at Teachers College, Columbia University and Albert Einstein College of Medicine have determined that health education programs can substantially increase the rates of dilated eye exams for African Americans with diabetes, the first step in reducing the risk of vision loss. The results were published in the December 1999 issue of the American Journal of Public Health.

English

08/29/14 6:33 am